Aclarion Inc (ACON)vsVeeva Systems Inc Class A (VEEV)
ACON
Aclarion Inc
$2.38
+0.85%
HEALTHCARE · Cap: $5.81M
VEEV
Veeva Systems Inc Class A
$211.86
+2.72%
HEALTHCARE · Cap: $33.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Veeva Systems Inc Class A generates 4261862% more annual revenue ($3.32B vs $77,880). VEEV leads profitability with a 28.4% profit margin vs 0.0%. VEEV earns a higher WallStSmart Score of 69/100 (B-).
ACON
Avoid29
out of 100
Grade: F
VEEV
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACON.
Margin of Safety
+38.9%
Fair Value
$289.59
Current Price
$211.86
$77.73 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 30.9%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Growing faster than its price suggests
16.3% revenue growth
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ACON
The strongest argument for ACON centers on Price/Book. Revenue growth of 11.3% demonstrates continued momentum.
Bull Case : VEEV
The strongest argument for VEEV centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 28.4% and operating margin at 30.9%. Revenue growth of 16.3% demonstrates continued momentum.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Bear Case : VEEV
The primary concerns for VEEV are P/E Ratio.
Key Dynamics to Monitor
ACON profiles as a value stock while VEEV is a growth play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.22 — expect wider price swings.
VEEV is growing revenue faster at 16.3% — sustainability is the question.
VEEV generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
VEEV scores higher overall (69/100 vs 29/100), backed by strong 28.4% margins and 16.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is a pioneering healthcare technology firm dedicated to advancing non-invasive diagnostic solutions for musculoskeletal conditions through cutting-edge imaging and data analytics. By harnessing the power of machine learning, Aclarion empowers healthcare providers with actionable insights that not only improve clinical outcomes but also optimize treatment pathways and reduce costs. Positioned at the forefront of the digital health revolution, the company is well-equipped to meet the rising demand for effective diagnostics, thereby significantly enhancing patient management and care standards in a dynamic healthcare landscape. Aclarion's commitment to improving patient care underscores its vital role in the future of healthcare delivery.
Visit Website →Veeva Systems Inc Class A
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?